86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

366 trials found

diseases per page:

Showing 1 to 10 of 366 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05660863 (ClinicalTrials.gov)	June 1, 2023	1/12/2022	A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets	A Bridged Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tol ...	Pulmonary Arterial Hypertension	Drug: MN-08 24 mg/day;Drug: MN-08 60 mg/day	Guangzhou Magpie Pharmaceuticals Co., Ltd.	NULL	Not yet recruiting	18 Years	45 Years	All	16	Phase 1	NULL
2	NCT05731492 (ClinicalTrials.gov)	March 28, 2023	9/2/2023	A Study of Macitentan in Children Below 2 Years of Age	A Multicenter, Open-label, Single-arm Study to Assess the Pharmacokinetics and Safety of Macitentan ...	Arterial Hypertension, Pulmonary	Drug: Macitentan	Actelion	NULL	Recruiting	1 Month	2 Years	All	10	Phase 1	Germany;Poland
3	NCT05764265 (ClinicalTrials.gov)	March 27, 2023	10/1/2023	Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants	An Open-label Extension Study to Investigate Efficacy, Safety and Tolerability of LTP001 in Particip ...	Pulmonary Arterial Hypertension	Drug: LTP001	Novartis Pharmaceuticals	NULL	Not yet recruiting	18 Years	75 Years	All	40	Phase 2	NULL
4	NCT05649748 (ClinicalTrials.gov)	February 28, 2023	6/12/2022	A Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil P ...	An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term ...	Pulmonary Arterial Hypertension	Drug: Treprostinil Palmitil;Drug: Placebo	Insmed Incorporated	NULL	Recruiting	18 Years	N/A	All	100	Phase 2/Phase 3	Japan
5	NCT04778046 (ClinicalTrials.gov)	February 15, 2023	26/2/2021	Pulmonary Hypertension SOLAR	Defining a Noninvasive Signature for Pulmonary Vascular Remodeling in Group 3 PH	Interstitial Lung Disease;COPD;Pulmonary Arterial Hypertension	Drug: Hyperpolarized 129Xe	Bastiaan Driehuys	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	United States
6	NCT05564637 (ClinicalTrials.gov)	February 2023	28/9/2022	A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension	Comprehensive O2 Transfer Analysis From the Lung to Mitochondria of Inhaled Treprostinil in Intersti ...	Pulmonary Arterial Hypertension;Interstitial Lung Disease;Healthy Adults	Drug: Treprostinil;Diagnostic Test: Right Heart Catheterization (RHC) while exercising;Diagnostic Te ...	Mayo Clinic	United Therapeutics	Recruiting	18 Years	N/A	All	18	Phase 2	United States
7	NCT05452889 (ClinicalTrials.gov)	January 31, 2023	9/6/2022	PET Image in PAH Patients	Utilizing 18F-fluoroglutamine PET Imaging in Patients With Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Diagnostic Test: 18F-FGLN PET Imaging;Drug: (18F)FPGLU	Stephen Y. Chan	Bayer;National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	18 Years	75 Years	All	50	Early Phase 1	United States
8	NCT05587712 (ClinicalTrials.gov)	January 19, 2023	17/10/2022	Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7 ...	A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam ...	Pulmonary Arterial Hypertension	Drug: Sotatercept	Merck Sharp & Dohme LLC	NULL	Recruiting	1 Year	17 Years	All	42	Phase 2	United States
9	NCT05179356 (ClinicalTrials.gov)	January 1, 2023	16/12/2021	Dapagliflozin in Pulmonary Arterial Hypertension	Effects of DAPAgliflozin on Cardiopulmonary Exercise Capacity and Hemodynamics in Pulmonary Arterial ...	Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension	Drug: Dapagliflozin 10 MG [Farxiga];Drug: Placebo	Mads Ersbøll	NULL	Not yet recruiting	18 Years	N/A	All	52	Phase 2	NULL
10	NCT05167825 (ClinicalTrials.gov)	November 14, 2022	24/11/2021	A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension	A Multicenter, Open-label, Phase III Study to Assess the Efficacy, Safety, and Pharmacokinetics of M ...	Pulmonary Arterial Hypertension	Drug: Macitentan	Janssen Pharmaceutical K.K.	NULL	Recruiting	3 Months	15 Years	All	6	Phase 3	Japan

First Previous1 2 3 4 5…37Next Last